Unknown

Dataset Information

Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.


ABSTRACT:

Objective

Lumateperone, a novel antipsychotic drug that was granted by the Food and Drug Administration (FDA) approval in December 2019, remains insufficiently explored for its adverse event profile. This study used the FDA Adverse Event Reporting System (FAERS) database to explore its potential safety issues.

Methods

This study conducted a retrospective analysis of FAERS data from the fourth quarter of 2019 to the third quarter of 2023, extracting reports related to lumateperone. Disproportionality analysis using Reporting Odds Ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) algorithms was employed to detect signals of adverse events (AEs).

Results

Our research processed 4,777 pertinent AE disclosures related to lumateperone, unveiling 125 sign

SUBMITTER: Zhao D 

PROVIDER: S-EPMC11111848 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature